6th World Summit on Heart, Stroke & Neurological Disorders August 31-September 01, 2018 Boston, Massachusetts, USA

Biography:

Oladepo Mutiu Lolade is currently studying for his Master’s degree at Department of Biochemistry, Adekunle Ajasin University, where he bagged his Bachelor’s degree. He is a fully baked, technically inclined, scientifically unbiased and self-motivated researcher with a good laboratory proficiency. He is presently a Scientific Officer at General Hospital Akure Ondo State,Nigeria. He is a competent and enthusiastic researcher with interest in Nutrition and Cardiovascular diseases. His keen interest understanding the contribution of African diet and nutrition to cardiovascular health has drove him into various research that make use of experimental animal models to investigate the effects of commonly consumed Nigerian foods on markers of cardiovascular health. 

Abstract:

Solanum anguivi is a semi-domestic indigenous vegetable very valuable in many African countries with potential to becoming a cultivated market vegetable in Nigeria.Uptake of Solanum anguivi cause hypoglycemic effect, hypertension e.t.c. The effect of Saponin from solanum anguivi on heart function of alloxan induced diabetic rat was investigated in this Study. Twenty four (24) rats of average weight 120g were randomly divided into six (6) groups A-F. Group A (control) rats were given 2.0ml of distilled water , Group B (Diabetic control), Group C to F were diabetic rats which were administered 20mg/kg , 40mg/kg and 80mg/kg Saponin from solanum anguivi respectively for 14 days. The results showed that there was a significant reduction in plasma glucose in the diabetic rat to almost the level in the Control. The result also shows that, there was a significant reduction in Aspartate Aminotransferase AST and Alanine aminotransferase ALT activities in serum and heart compare with the control (p<0.05). This study show that solanum anguivi fruit has anti-diabetic effect on alloxan induced diabetic rat.

Biography:

Prior to founding Alzheon, Dr. Tolar has held executive positions in life sciences companies, where he has successfully established and grown new companies, business areas and product opportunities. Dr. Tolar served as President & CEO of Knome, Inc., he pioneered human genome interpretation systems and services for academic, pharmaceutical and clinical clients, as President & CEO at NormOxys, Inc., he built and financed the business for novel cancer therapeutics, and as CSO and CBO at CoMentis, Inc., he built the first clinical beta secretase inhibitor platform, and negotiated a landmark deal for the program for $1.1 billion with Astellas Pharma in 2008. Dr. Tolar held a variety of clinical development and business leadership positions at Pfizer, was instrumental in a wide range of business transactions, including acquisition of Rinat Neuroscience for $500 million in 2006, and directed programs through all stages of clinical development and FDA approvals including NDA filings.

Abstract:

Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimer’s clinical candidate, ALZ-801, is a Phase 3-ready, first-in-class, small molecule oral inhibitor of amyloid aggregation and neurotoxicity – hallmarks of Alzheimer’s disease. ALZ-801 is a novel prodrug that builds on the safety and efficacy profile of the active compound tramiprosate, which has been evaluated in clinical trials involving over 2,000 Alzheimer’s patients. Our clinical expertise and technology platform is focused on developing drug candidates using a Precision Medicine approach based on individual genetic and biological information to advance therapies with the greatest impact for patients.

ALZ-801 is a novel, oral anti-amyloid drug candidate that is an optimized prodrug of tramiprosate, which has shown promising results in analyses of clinical data and therapeutic mechanism of action. This includes the discovery of its novel molecular mechanism of action blocking the formation of toxic amyloid oligomers¹ associated with the development and progression of AD.  The clinical data for ALZ-801 and its active agent, tramiprosate, suggest long-term clinical efficacy in AD patients with the APOE4 genotype, along with a favorable safety profile. The initial Phase 3 program for ALZ-801 will focus on patients with the homozygous APOE4/4 genotype at the Mild stage of AD, with the potential for future expansion to additional Alzheimer’s populations. ALZ-801 received Fast Track designation by the U.S. Food and Drug Administration (FDA) in October 2017.

Biography:

Francesco Massari MD, PhD, is an Interventional Neuroradiologist at the University of Massachusetts, MA, USA. Dr. Massari obtained his Medical Degree, Ph.D. and Master Degree at the University of Rome “Tor Vergata”, Italy. He completed two fellowship programs in Diagnostic and Interventional Neuroradiology, respectively at the Medical University of South Carolina, SC, USA and University of Massachusetts, MA, USA; where he received an advanced training in Brain and Spine Interventional Radiology. His research spans areas including the cerebrovascular pathology and spinal disease. He is Principal Investigator (PI) and Co-Investigator in several clinical and laboratory international trials. He is an active member of several European and American Medical Societies, among which the American Medical Association (AMA), American Society of Neuroradiology (ASNR), Society of Neurointerventional Surgery (SNIS), American Society of Spine Radiology (ASSR), European Society of Radiology (ESR) and Cardiovascular and Interventional Radiology Society of Europe (CIRSE), as well as reviewer for multiple International Scientific Journals. His work has been presented at multiple national and international meetings and been published in scientific journals such as New England Journal of Medicine, Spine, Journal of Neurointerventional Surgery, Neuroradiology, Skeletal Radiology, Neurographics. He has been nominated for and won multiple awards at the American Society of Spine Radiology (ASSR) Annual Meeting for his research on spinal minimally invasive treatments.

Abstract:

Acute ischemic stroke (AIS) is the fifth leading cause of death, and remains the leading cause of disability in the USA. There are an estimated 680 000 new strokes per year in the USA, with a mortality rate of 53–94%, and with an even greater morbidity. Ischemic strokes are most commonly caused by either a rupture of an atherosclerotic plaque or by a blood clot that forms in another part of the body and travels into the brain. Ischemic strokes can occur suddenly and can lead to devastating consequences. Timely recognition and response is critical.

It is estimated that 3–22% of these patients are candidates for endovascular therapy. In addition to baseline stroke severity, emergent large vessel occlusion (ELVO) has been shown to be an independent predictor of poor outcome at 6 months. While intravenous recombinant tissue plasminogen activator (IV r-tPA) has proven efficacious predominantly for small cerebral vessel occlusions, endovascular therapies, including stent retriever based, aspiration based mechanical thrombectomy techniques, and intra-arterial administration of thrombolytic agents, have been shown to achieve higher rates of recanalization in patients with ELVO. The importance of quickly treating patients with acute ischemic stroke has been borne out in several studies, demonstrating the fact that the faster a patient’s blood flow to the brain is restored, the faster they will recover. The goal of quickly restoring blood flow to the brain is to provide patients with the best chance at a good recovery.

Biography:

I (Iwezu Happy Nonso) have my expertise in sports medicine (physiotherapy) and passion in improving the health and wellbeing. My open and contextual evaluation model based on responsive constructivists creates new pathways for improving healthcare. I have developed this model after years of experience in research, evaluation, teaching and administration both in hospital, outreach programs and education institutions. This will go a long way in restoring man back to form and function physically via spatial  neuroplasticity.

Abstract:

Central obesity and its implicated adverse health conditions are a major concern of some people. Central obesity is one of the predisposition factors to cardiovascular disease, respiratory conditions, type 2 diabetes mellitus, cancer and others. The purpose of this study was to determine the relationship between central obesity, cardio respiratory fitness and physical activity level among adults in Enugu State. 

Three hundred and seventeen subjects (158 obese and 159 non obese ) who met the inclusion criteria and gave their informed consent participated in the study. Their waist to hip ratio was determined using measuring tape. Body Mass Index measured with stadiometer and weighing scale. Cardio respiratory fitness was determined using Harvard Step Test and International Physical Activity Questionnaire (IPAQ) was  used to determine their physical activity level. Data collected was analyzed descriptively and inferentially using correlation test. The level of significance was set at p = 0.01

 The physical activity level of obese adults in Enugu state increases in an ascending order of vigorous, low, moderate while the cardiorespiratory fitness decreases in reverse direction as low, average, good, excellence and very low. There was a significant relationship between cardio respiratory fitness and physical activity (r = 0.146, sig = 0.009). There was also a significant relationship  between waist-hip ratio and cardiorespiratory fitness (r=-0.221,sig=0.000)

keywords: obesity, cardiorespiratory fitness, physical activity level, adults

In this seminar, I will discuss the effect of central obesity on cardio-respiratory fitness, and physical activity on adults and its pathophysiology.